カテゴリ： FactMR, 世界, 医療/バイオ

ペプチドベース心臓血管治療薬のグローバル市場2023～2033：ビバリルジン、エプチフィバチド

■ 英語タイトル：Peptide-based Cardiovascular Therapeutics Market By Drug (Bivalirudin, Eptifibatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region – Global Market Insights 2023 to 2033

調査会社FactMR社が発行したリサーチレポート（データ管理コード：FACT23MA040）■ 発行会社/調査会社：FactMR
■ 商品コード：FACT23MA040
■ 発行日：2023年4月12日
   最新版(2025年又は2026年)はお問い合わせください。
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：約170
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール
■ 販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）見積依頼/購入/質問フォーム
Global Sie License（同一拠点内共有可）見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※FactMR社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ペプチドベース心臓血管治療薬のグローバル市場2023～2033：ビバリルジン、エプチフィバチド]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Fact.MR社の本市場調査レポートは、予測期間（2023年〜2033年）における世界のペプチドベース心臓血管治療薬市場について、市場状況や動向を推測した資料です。本レポートは、エグゼクティブサマリー、市場概要、治療薬別（ビバリルジン、エプチフィバチド）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、中南米、ヨーロッパ、日本、アジア太平洋、中東・アフリカ）分析、競争状況・企業情報、調査手法、一次情報源・二次情報源、仮定などの項目を掲載しています。また、本書内には、AstraZeneca plc、CordenPharma International、Ipsen S.Aなど、主要企業情報を含んでいます。
・エグゼクティブサマリー
・市場概要
・世界のペプチドベース心臓血管治療薬市場規模：治療薬別
- ビバリルジンの市場規模
- エプチフィバチドの市場規模
・世界のペプチドベース心臓血管治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のペプチドベース心臓血管治療薬市場規模：地域別
- 北米のペプチドベース心臓血管治療薬市場規模
- 中南米のペプチドベース心臓血管治療薬市場規模
- ヨーロッパのペプチドベース心臓血管治療薬市場規模
- 日本のペプチドベース心臓血管治療薬市場規模
- アジア太平洋のペプチドベース心臓血管治療薬市場規模
- 中東・アフリカのペプチドベース心臓血管治療薬市場規模
・競争状況・企業情報
・調査手法
・一次情報源・二次情報源
・仮定

本書には、各参入企業の製品ポートフォリオ、主要戦略及び包括的なSWOT分析などの要素を含む企業情報が含まれています。企業のプレゼンスは、全著名プレーヤーについてマッピングされ、マトリックスにより提供されます。したがって、レポートの読者に実用的洞察を提示し、熟考して市場状況を提供し、ペプチドベース心臓血管治療薬における競争レベルを予想するのに活用できます。

PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS Market – Scope of Report

A recent study by Fact.MR on the PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering Peptide-based Cardiovascular Therapeutics.
The study also provides the dynamics responsible for influencing the future status of the PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS market during the forecast period.
Country-specific valuation on demand for PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of XYZ, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the PEPTIDE-BASED CARDIOVASCULAR THERAPEUTICS domain.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Global Market – Executive Summary

2. Global Market Overview

    2.1. Introduction

        2.1.1. Global Market Taxonomy

        2.1.2. Global Market Definition

    2.2. Global Market Size (US$ Mn) and Forecast, 2018-2033

        2.2.1. Global Market Y-o-Y Growth

    2.3. Global Market Dynamics

    2.4. Regulations

    2.5. Supply Chain

    2.6. Cost Structure

    2.7. Average Pricing Analysis

    2.8. Epidemiology

    2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Market Analysis and Forecast By Drug

    3.1. Global Market Size and Forecast By Drug, 2018-2033

        3.1.1. Bivalirudin Market Size and Forecast, 2018-2033

            3.1.1.1. Revenue (US$ Mn) Comparison, By Region

            3.1.1.2. Market Share Comparison, By Region

            3.1.1.3. Y-o-Y growth Comparison, By Region

        3.1.2. Eptifibatide Market Size and Forecast, 2018-2033

            3.1.2.1. Revenue (US$ Mn) Comparison, By Region

            3.1.2.2. Market Share Comparison, By Region

            3.1.2.3. Y-o-Y growth Comparison, By Region

4. Global Market Analysis and Forecast By Distribution Channel

    4.1. Global Market Size and Forecast By Distribution Channel, 2018-2033

        4.1.1. Hospital Pharmacies Market Size and Forecast, 2018-2033

            4.1.1.1. Revenue (US$ Mn) Comparison, By Region

            4.1.1.2. Market Share Comparison, By Region

            4.1.1.3. Y-o-Y growth Comparison, By Region

        4.1.2. Retail Pharmacies Market Size and Forecast, 2018-2033

            4.1.2.1. Revenue (US$ Mn) Comparison, By Region

            4.1.2.2. Market Share Comparison, By Region

            4.1.2.3. Y-o-Y growth Comparison, By Region

        4.1.3. Online Pharmacies Market Size and Forecast, 2018-2033

            4.1.3.1. Revenue (US$ Mn) Comparison, By Region

            4.1.3.2. Market Share Comparison, By Region

            4.1.3.3. Y-o-Y growth Comparison, By Region

5. Global Market Analysis and Forecast By Region

    5.1. Global Market Size and Forecast, 2018-2033

        5.1.1. North America Market Size and Forecast, 2018-2033

            5.1.1.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

        5.1.2. Latin America Market Size and Forecast, 2018-2033

            5.1.2.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

        5.1.3. Europe Market Size and Forecast, 2018-2033

            5.1.3.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel

        5.1.4. Japan Market Size and Forecast, 2018-2033

            5.1.4.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel

        5.1.5. APEJ Market Size and Forecast, 2018-2033

            5.1.5.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel

        5.1.6. MEA Market Size and Forecast, 2018-2033

            5.1.6.1. Revenue (US$ Mn) Comparison, By Drug

            5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel

6. North America Market Analysis and Forecast, By Country, 2018-2033

    6.1. US Market Size and Forecast, 2018-2033

        6.1.1. Revenue (US$ Mn) Comparison, By Drug

        6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    6.2. Canada Market Size and Forecast, 2018-2033

        6.2.1. Revenue (US$ Mn) Comparison, By Drug

        6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Latin America Market Analysis and Forecast, By Country, 2018-2033

    7.1. Brazil Market Size and Forecast, 2018-2033

        7.1.1. Revenue (US$ Mn) Comparison, By Drug

        7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    7.2. Mexico Market Size and Forecast, 2018-2033

        7.2.1. Revenue (US$ Mn) Comparison, By Drug

        7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    7.3. Argentina Market Size and Forecast, 2018-2033

        7.3.1. Revenue (US$ Mn) Comparison, By Drug

        7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel

8. Europe Market Analysis and Forecast, By Country, 2018-2033

    8.1. Germany Market Size and Forecast, 2018-2033

        8.1.1. Revenue (US$ Mn) Comparison, By Drug

        8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    8.2. UK Market Size and Forecast, 2018-2033

        8.2.1. Revenue (US$ Mn) Comparison, By Drug

        8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    8.3. France Market Size and Forecast, 2018-2033

        8.3.1. Revenue (US$ Mn) Comparison, By Drug

        8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    8.4. Spain Market Size and Forecast, 2018-2033

        8.4.1. Revenue (US$ Mn) Comparison, By Drug

        8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    8.5. Italy Market Size and Forecast, 2018-2033

        8.5.1. Revenue (US$ Mn) Comparison, By Drug

        8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    8.6. Nordic Market Size and Forecast, 2018-2033

        8.6.1. Revenue (US$ Mn) Comparison, By Drug

        8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel

9. Japan Market Analysis and Forecast, By Country, 2018-2033

    9.1. Japan Market Size and Forecast, 2018-2033

        9.1.1. Revenue (US$ Mn) Comparison, By Drug

        9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

10. APEJ Market Analysis and Forecast, By Country, 2018-2033

    10.1. China Market Size and Forecast, 2018-2033

        10.1.1. Revenue (US$ Mn) Comparison, By Drug

        10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    10.2. India Market Size and Forecast, 2018-2033

        10.2.1. Revenue (US$ Mn) Comparison, By Drug

        10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    10.3. Malaysia Market Size and Forecast, 2018-2033

        10.3.1. Revenue (US$ Mn) Comparison, By Drug

        10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    10.4. Thailand Market Size and Forecast, 2018-2033

        10.4.1. Revenue (US$ Mn) Comparison, By Drug

        10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    10.5. Singapore Market Size and Forecast, 2018-2033

        10.5.1. Revenue (US$ Mn) Comparison, By Drug

        10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    10.6. Australia Market Size and Forecast, 2018-2033

        10.6.1. Revenue (US$ Mn) Comparison, By Drug

        10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel

11. MEA Market Analysis and Forecast, By Country, 2018-2033

    11.1. GCC Countries Market Size and Forecast, 2018-2033

        11.1.1. Revenue (US$ Mn) Comparison, By Drug

        11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    11.2. South Africa Market Size and Forecast, 2018-2033

        11.2.1. Revenue (US$ Mn) Comparison, By Drug

        11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    11.3. Nigeria Market Size and Forecast, 2018-2033

        11.3.1. Revenue (US$ Mn) Comparison, By Drug

        11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel

    11.4. Israel Market Size and Forecast, 2018-2033

        11.4.1. Revenue (US$ Mn) Comparison, By Drug

        11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel

12. Global Market Competition Landscape and Company Profile

    12.1. Company Share Analysis By Region

        12.1.1. AstraZeneca plc

            12.1.1.1. Company Overview

            12.1.1.2. Market Drug list

            12.1.1.3. Market Drug Sales Data and Key Financials

            12.1.1.4. Key Developments

            12.1.1.5. SWOT Analysis

        12.1.2. CordenPharma International

            12.1.2.1. Company Overview

            12.1.2.2. Market Drug list

            12.1.2.3. Market Drug Sales Data and Key Financials

            12.1.2.4. Key Developments

            12.1.2.5. SWOT Analysis

        12.1.3. Ipsen S.A

            12.1.3.1. Company Overview

            12.1.3.2. Market Drug list

            12.1.3.3. Market Drug Sales Data and Key Financials

            12.1.3.4. Key Developments

            12.1.3.5. SWOT Analysis

        12.1.4. Merck & Co., Inc

            12.1.4.1. Company Overview

            12.1.4.2. Market Drug list

            12.1.4.3. Market Drug Sales Data and Key Financials

            12.1.4.4. Key Developments

            12.1.4.5. SWOT Analysis

        12.1.5. Pfizer Inc.

            12.1.5.1. Company Overview

            12.1.5.2. Market Drug list

            12.1.5.3. Market Drug Sales Data and Key Financials

            12.1.5.4. Key Developments

            12.1.5.5. SWOT Analysis

        12.1.6. Apotex Holdings, Inc.

            12.1.6.1. Company Overview

            12.1.6.2. Market Drug list

            12.1.6.3. Market Drug Sales Data and Key Financials

            12.1.6.4. Key Developments

            12.1.6.5. SWOT Analysis

        12.1.7. Dr. Reddy’s Laboratories Limited

            12.1.7.1. Company Overview

            12.1.7.2. Market Drug list

            12.1.7.3. Market Drug Sales Data and Key Financials

            12.1.7.4. Key Developments

            12.1.7.5. SWOT Analysis

        12.1.8. Fresenius Kabi USA, LLC

            12.1.8.1. Company Overview

            12.1.8.2. Market Drug list

            12.1.8.3. Market Drug Sales Data and Key Financials

            12.1.8.4. Key Developments

            12.1.8.5. SWOT Analysis

        12.1.9. Novetide Ltd

            12.1.9.1. Company Overview

            12.1.9.2. Market Drug list

            12.1.9.3. Market Drug Sales Data and Key Financials

            12.1.9.4. Key Developments

            12.1.9.5. SWOT Analysis

        12.1.10. Amneal Pharmaceuticals LLC

            12.1.10.1. Company Overview

            12.1.10.2. Market Drug list

            12.1.10.3. Market Drug Sales Data and Key Financials

            12.1.10.4. Key Developments

            12.1.10.5. SWOT Analysis

13. Research Methodology

14. Secondary and Primary Sources

15. Assumptions and Acronyms

16. Disclaimer

TABLE 01: Global Market Value (US$ Mn), 2018-2022

TABLE 02: Global Market Value (US$ Mn), 2023-2033

TABLE 03: Global Market Value (US$ Mn) and Y-o-Y, 2015-2033

TABLE 04: Global Bivalirudin Segment Value (US$ Mn), By Region 2018-2022

TABLE 05: Global Bivalirudin Segment Value (US$ Mn), By Region 2023-2033

TABLE 06: Global Bivalirudin Segment Market Share, By Region 2018-2022

TABLE 07: Global Bivalirudin Segment Market Share, By Region 2023-2033

TABLE 08: Global Bivalirudin Segment Y-o-Y, By Region 2015-2033

TABLE 09: Global Eptifibatide Segment Value (US$ Mn), By Region 2018-2022

TABLE 10: Global Eptifibatide Segment Value (US$ Mn), By Region 2023-2033

TABLE 11: Global Eptifibatide Segment Market Share, By Region 2018-2022

TABLE 12: Global Eptifibatide Segment Market Share, By Region 2023-2033

TABLE 13: Global Eptifibatide Segment Y-o-Y, By Region 2015-2033

TABLE 14: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2022

TABLE 15: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2023-2033

TABLE 16: Global Hospital Pharmacies Segment Market Share, By Region 2018-2022

TABLE 17: Global Hospital Pharmacies Segment Market Share, By Region 2023-2033

TABLE 18: Global Hospital Pharmacies Segment Y-o-Y, By Region 2015-2033

TABLE 19: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2022

TABLE 20: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2023-2033

TABLE 21: Global Retail Pharmacies Segment Market Share, By Region 2018-2022

TABLE 22: Global Retail Pharmacies Segment Market Share, By Region 2023-2033

TABLE 23: Global Retail Pharmacies Segment Y-o-Y, By Region 2015-2033

TABLE 24: Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2022

TABLE 25: Global Online Pharmacies Segment Value (US$ Mn), By Region 2023-2033

TABLE 26: Global Online Pharmacies Segment Market Share, By Region 2018-2022

TABLE 27: Global Online Pharmacies Segment Market Share, By Region 2023-2033

TABLE 28: Global Online Pharmacies Segment Y-o-Y, By Region 2015-2033

TABLE 29: North America Market Value (US$ Mn), By Drug 2018-2022

TABLE 30: North America Market Value (US$ Mn), By Drug 2023-2033

TABLE 31: North America Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 32: North America Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 33: Latin America Market Value (US$ Mn), By Drug 2018-2022

TABLE 34: Latin America Market Value (US$ Mn), By Drug 2023-2033

TABLE 35: Latin America Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 36: Latin America Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 37: Europe Market Value (US$ Mn), By Drug 2018-2022

TABLE 38: Europe Market Value (US$ Mn), By Drug 2023-2033

TABLE 39: Europe Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 40: Europe Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 41: Japan Market Value (US$ Mn), By Drug 2018-2022

TABLE 42: Japan Market Value (US$ Mn), By Drug 2023-2033

TABLE 43: Japan Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 44: Japan Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 45: APEJ Market Value (US$ Mn), By Drug 2018-2022

TABLE 46: APEJ Market Value (US$ Mn), By Drug 2023-2033

TABLE 47: APEJ Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 48: APEJ Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 49: MEA Market Value (US$ Mn), By Drug 2018-2022

TABLE 50: MEA Market Value (US$ Mn), By Drug 2023-2033

TABLE 51: MEA Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 52: MEA Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 53: US Market Value (US$ Mn), By Drug 2018-2022

TABLE 54: US Market Value (US$ Mn), By Drug 2023-2033

TABLE 55: US Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 56: US Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 57: Canada Market Value (US$ Mn), By Drug 2018-2022

TABLE 58: Canada Market Value (US$ Mn), By Drug 2023-2033

TABLE 59: Canada Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 60: Canada Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 61: Brazil Market Value (US$ Mn), By Drug 2018-2022

TABLE 62: Brazil Market Value (US$ Mn), By Drug 2023-2033

TABLE 63: Brazil Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 64: Brazil Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 65: Mexico Market Value (US$ Mn), By Drug 2018-2022

TABLE 66: Mexico Market Value (US$ Mn), By Drug 2023-2033

TABLE 67: Mexico Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 68: Mexico Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 69: Argentina Market Value (US$ Mn), By Drug 2018-2022

TABLE 70: Argentina Market Value (US$ Mn), By Drug 2023-2033

TABLE 71: Argentina Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 72: Argentina Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 73: Germany Market Value (US$ Mn), By Drug 2018-2022

TABLE 74: Germany Market Value (US$ Mn), By Drug 2023-2033

TABLE 75: Germany Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 76: Germany Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 77: UK Market Value (US$ Mn), By Drug 2018-2022

TABLE 78: UK Market Value (US$ Mn), By Drug 2023-2033

TABLE 79: UK Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 80: UK Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 81: France Market Value (US$ Mn), By Drug 2018-2022

TABLE 82: France Market Value (US$ Mn), By Drug 2023-2033

TABLE 83: France Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 84: France Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 85: Spain Market Value (US$ Mn), By Drug 2018-2022

TABLE 86: Spain Market Value (US$ Mn), By Drug 2023-2033

TABLE 87: Spain Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 88: Spain Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 89: Italy Market Value (US$ Mn), By Drug 2018-2022

TABLE 90: Italy Market Value (US$ Mn), By Drug 2023-2033

TABLE 91: Italy Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 92: Italy Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 93: Nordic Market Value (US$ Mn), By Drug 2018-2022

TABLE 94: Nordic Market Value (US$ Mn), By Drug 2023-2033

TABLE 95: Nordic Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 96: Nordic Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 97: Japan Market Value (US$ Mn), By Drug 2018-2022

TABLE 98: Japan Market Value (US$ Mn), By Drug 2023-2033

TABLE 99: Japan Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 100: Japan Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 101: China Market Value (US$ Mn), By Drug 2018-2022

TABLE 102: China Market Value (US$ Mn), By Drug 2023-2033

TABLE 103: China Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 104: China Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 105: India Market Value (US$ Mn), By Drug 2018-2022

TABLE 106: India Market Value (US$ Mn), By Drug 2023-2033

TABLE 107: India Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 108: India Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 109: Malaysia Market Value (US$ Mn), By Drug 2018-2022

TABLE 110: Malaysia Market Value (US$ Mn), By Drug 2023-2033

TABLE 111: Malaysia Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 112: Malaysia Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 113: Thailand Market Value (US$ Mn), By Drug 2018-2022

TABLE 114: Thailand Market Value (US$ Mn), By Drug 2023-2033

TABLE 115: Thailand Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 116: Thailand Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 117: Singapore Market Value (US$ Mn), By Drug 2018-2022

TABLE 118: Singapore Market Value (US$ Mn), By Drug 2023-2033

TABLE 119: Singapore Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 120: Singapore Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 121: Australia Market Value (US$ Mn), By Drug 2018-2022

TABLE 122: Australia Market Value (US$ Mn), By Drug 2023-2033

TABLE 123: Australia Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 124: Australia Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 125: GCC Countries Market Value (US$ Mn), By Drug 2018-2022

TABLE 126: GCC Countries Market Value (US$ Mn), By Drug 2023-2033

TABLE 127: GCC Countries Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 128: GCC Countries Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 129: South Africa Market Value (US$ Mn), By Drug 2018-2022

TABLE 130: South Africa Market Value (US$ Mn), By Drug 2023-2033

TABLE 131: South Africa Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 132: South Africa Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 133: Nigeria Market Value (US$ Mn), By Drug 2018-2022

TABLE 134: Nigeria Market Value (US$ Mn), By Drug 2023-2033

TABLE 135: Nigeria Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 136: Nigeria Market Value (US$ Mn), By Distribution Channel 2023-2033

TABLE 137: Israel Market Value (US$ Mn), By Drug 2018-2022

TABLE 138: Israel Market Value (US$ Mn), By Drug 2023-2033

TABLE 139: Israel Market Value (US$ Mn), By Distribution Channel 2018-2022

TABLE 140: Israel Market Value (US$ Mn), By Distribution Channel 2023-2033
※参考情報

ペプチドベース心臓血管治療薬とは、ペプチドを基盤とした化合物であり、心血管系の疾患に対して治療効果を持つ医薬品のことを指します。ペプチドはアミノ酸が結合した小さなタンパク質であり、特定の生物学的機能を持つことから、様々な疾患の治療に有用です。心臓血管系の疾患は、心筋梗塞や心不全、高血圧、動脈硬化など多岐にわたりますが、ペプチドはこれらの疾患に対して新しい治療の選択肢を提供します。

ペプチドベース心臓血管治療薬には、いくつかの種類があります。一つは、ホルモンや神経伝達物質に類似した機能を持つペプチドです。これらのペプチドは、心臓の機能を調整したり、血管の拡張を促進する作用があります。例えば、アナトミンやアドレナリン受容体に作用するペプチドは、心拍数や血圧をコントロールするのに役立ちます。

異なるペプチドの医薬品もあります。これには、心筋の保護や再生を促進するペプチド治療薬があります。これらの治療薬は、心筋細胞の新生や機能の改善を目指したもので、特に心不全の治療において期待されています。さらに、動脈硬化や心筋梗塞の予防に役立つペプチドも注目されています。

これらのペプチド治療薬は、投与方法としては主に注射によるものが多いですが、一部は経口投与も可能です。ペプチドは比較的小さな分子であるため、体内での吸収や代謝において利点があります。また、ペプチドは特異的な受容体に結合することで作用し、副作用が少ないというメリットもあります。

ペプチドベースの治療薬は、通常の小分子薬と比較しても、治療の効果が高く、よりターゲットに応じた作用が期待できます。しかし、ペプチドの安定性や体内での半減期が短いため、投与が困難な場合があり、これに対する工夫が求められます。最近では、ペプチドの改良や変異体の開発が進められ、効果的かつ安全な治療薬の開発が行われています。

技術的には、ペプチドベースの治療薬の開発には、合成化学やバイオテクノロジーが重要な役割を果たしています。特に、合成ペプチドの開発やモデリング技術は、より高い特異性を持つペプチドをデザインするために用いられています。また、ペプチドの構造の改変やナノキャリア技術を用いたドラッグデリバリーシステムも注目されています。これにより、ペプチド薬の運搬効率や体内での持続時間を改善することが可能になります。

心血管疾患は世界的に重大な健康問題であり、メタボリックシンドロームや生活習慣病の影響でその prevalence（有病率）は増加しています。この状況に対処するためにも、ペプチドベース心臓血管治療薬の研究開発は非常に重要な意義を持ちます。

また、ペプチド治療薬は、従来の治療法に比べて新しいアプローチを提供しており、併用療法としても有効性が期待されています。例えば、従来の薬剤と組み合わせることで相乗効果が得られる可能性があります。このような基礎的な研究の進展が、今後の心血管治療におけるペプチドの役割をさらに明確にすることが期待されています。

今後も、ペプチドベース心臓血管治療薬は、心血管疾患の治療においてその有効性が期待され続けるでしょう。最新の研究成果をもとに、より効果的で安全な治療法が提供されることを願っています。科学技術の進展により、心血管系疾患の新たな治療可能性が広がることが期待されているのです。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ペプチド感染症治療薬のグローバル市場2023～2033：テラプレビル、ボセプレビル
  • ペプチド治療薬（メタボリックシンドローム用）のグローバル市場2023～2033：リラグルチド、エキセナチド、その他
  • 小児医療用OTC医薬品のグローバル市場2023～2033：胃腸科、皮膚科、ENT（耳鼻咽喉科）、栄養剤/ビタミン
  • プレフィルドオートインジェクター（薬剤充填済み自動注射器）のグローバル市場2023～2033：アナフィラキシー、多発性硬化症、関節リウマチ、その他
  • 細胞株開発のグローバル市場2023～2033：免疫療法細胞株、イオンチャネル細胞株、GPCR細胞株、細胞シグナル伝達経路用細胞株、遺伝子ノックアウト細胞株、がん細胞株
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(FACT23MA040 )"ペプチドベース心臓血管治療薬のグローバル市場2023～2033：ビバリルジン、エプチフィバチド" (英文：Peptide-based Cardiovascular Therapeutics Market By Drug (Bivalirudin, Eptifibatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region – Global Market Insights 2023 to 2033)はFactMR社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。